(CercleFinance.com) – The British consumer healthcare group Haleon, a spin-off from the giant GSK, reported on Tuesday a turnover up 13% to 5.2 billion pounds for the first half.
In organic terms, organic sales growth was 11.6% over the first six months of the year, including an increase of 3.7% linked to prices and 7.9% in terms of volumes.
In its press release, Haleon highlights the good performance of several of its non-prescription drugs, such as Panadol (paracetamol), Theraflu (colds and flu), Otrivin (nasal decongestant), Advil (painkiller) and Centrum (multi-vitamins). .
Its adjusted operating profit thus increased by 21% to nearly 1.2 billion pounds over the quarter, including an increase of 15.5% at constant exchange rates.
The company also confirmed that it is aiming for organic growth of 6% to 8% over the full year.
In a reaction note, RBC analysts refer to a “solid” publication, but deplore the lack of information concerning the Zantac file, the main driver of the stock price according to them for the moment.
In its press release, Haleon simply indicates that it rejected the compensation claims made by GSK and Pfizer on the grounds that their joint venture was not created until 2018, when they no longer marketed the drug.
This is Haleon’s first earnings release since its IPO on July 18. The stock has now gained more than 2%, but has fallen nearly 20% since its first listing.
Copyright (c) 2022 CercleFinance.com. All rights reserved.